Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

eading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional clinical-stage cannabinoid product candidates targeting epilepsy (including an orphan pediatric epilepsy program), Type 2 diabetes, ulcerative colitis, glioma and schizophrenia. For further information, please visit www.gwpharm.com.

Forward-looking statements

This news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including statements regarding our clinical goals, our plans for a clinical trial, the ability to conduct clinical trials sufficient to achieve positive completion, and the therapeutic and commercial value of the company's compounds. To the degree we are able to conduct clinical trials, we may have difficulty in enrolling candidates for testing and we may not be able to achieve the desired results. Forward-looking statements involve risks and uncertainties.  Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex® and other products by consumer and medical professionals. A further list and description of risks, uncertainties and other risks associated with an investment in GW can be found in GW's filings with the U.S. Securities and Exchange Commission, including the prospectus related to the NASDAQ offering filed by GW with the SEC on May 1, 2013. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result o
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014 Polaris Group announced ... in its Phase 1 trial of ADI-PEG 20 ... treatment of malignant pleural mesothelioma (MPM) and non-squamous ... clinical trials on ADI-PEG 20, both as monotherapy ... treatment of several other indications, including breast cancer, ...
(Date:11/21/2014)... ON , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and nine month periods ended September 30, 2014.  Biorem,s complete 2014 ... ( www.sedar.com ). Financial Summary:Three-months ended September ... except per share data) , 2014 , ... 2,282 , 5,281 , 6,715 ...
(Date:11/18/2014)... November 17, 2014 Cirrascale ... architecture blade-based and rackmount computing infrastructure, today announced ... dual-GPU accelerator throughout its GPU-enabled blade server and ... the company’s latest proprietary 80-lane Gen3 PCIe switch-enabled ... NVIDIA Tesla K80 dual-GPU accelerator cards in a ...
(Date:11/18/2014)... (PRWEB) November 18, 2014 Alanda ... and Transparency Reporting solutions, announced today that a ... using its Consummate Provider™ solution in both the ... a Global, SaaS based, Data Quality remediation portal, ... their third party Providers improve their ability to ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... ForteBio(R), Inc., a leading supplier of label-free technology ... products, announced today that it has launched two ... small molecule and fragment screening; and the Octet ... instruments will debut this week at the 2009 ...
... , WASHINGTON, June 22 Pharmaceutical ... Tauzin today issued the following statement regarding today,s AARP-White House ... the strong support of AARP, we believe this agreement will ... the legislative efforts to reform our troubled health care system. ...
... in consumer probiotics expands into livestock industry with Direct ... June 22 Ganeden Biotech, Inc., the largest seller ... launch of GanPro(TM), an all-natural animal feed additive containing ... support gut health and naturally promote feed conversion in ...
Cached Biology Technology:ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet(R) RED384 and the Octet QK384 2ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet(R) RED384 and the Octet QK384 3PhRMA Statement on AARP-White House Press Conference 2Ganeden Biotech Introduces GanPro(TM) Direct-Fed Microbial for Livestock 2
(Date:11/5/2014)... professor of biology in the UTSA College of ... nation selected to receive a two-year $300,00 National ... Research (EAGER). The funding supports President Obama,s BRAIN ... create new technology that will demystify complex brain ... in neuroscience are broken into the interactions of ...
(Date:11/4/2014)... School of Medicine announced today that it is ... by the Bill & Melinda Gates Foundation. ... and Reproductive Sciences; and Vice Chair of Research ... Medicine will pursue an innovative global health and ... Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds ...
(Date:11/4/2014)...   Neurotechnology , a provider of high-precision ... version of its fingerprint matching algorithm has achieved ... evaluation organized by NIST. The MINEX test measures ... 378 fingerprint standard template format. MINEX compliance is ... the United States and ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Temple University School of Medicine receives Grand Challenges Explorations grant 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3
... Nearly 90 percent of children and adults with a ... no evidence of cancer after receiving a novel, personalized ... pilot studies of bioengineered T cells that attack leukemia, ... 28 days after treatment. In all, 27 patients received ...
... international project has developed a free and open public ... and contentious world of gene patenting. In a ... published in this week,s Nature Biotechnology journal, ... keep up with the rapid explosion in information and ...
... Sophisticated recent experiments with ultrashort laser pulses support the ... algae, and some bacteria efficiently gather light to fuel ... mechanisms remain obscure, and the exact role that quantum ... than was once thought, according to an Overview Article ...
Cached Biology News:T cell immunotherapy: Promising results in children and adults with leukemia 2T cell immunotherapy: Promising results in children and adults with leukemia 3Who's patenting whose genome? 2Who's patenting whose genome? 3Quantum effects help cells capture light, but the details are obscure 2
... a positive control for ChIP assays. Efficient ... vivo is a crucial step for the ... is probably the most important parameter. Two ... should be taken into account: first, an ...
... Major Science MS 300V (Cat. No. MP-300V) ... to meet most electrophoresis needs in a ... Science MS 300V power supply provides ... used in electrophoresis. 4 pairs of terminator ...
Rab GDP dissociation inhibitor beta...
... Scientific has a long and outstanding ... apparatus. Several years ago we became ... microdispenser was being modified to inject ... by redesigning the microdispenser to eliminate ...
Biology Products: